Biopharmaceutical companies are tasked with doing more with less while moving promising biotherapeutics into the clinic as fast as safely possible. Advances in High-Throughput Upstream Process Development takes a deep dive into an approach that addresses this challenge: combining definitive screening designs with advanced machine learning for accelerated drug development. Explore: